Table 4. Summary of published studies on 6-12mo visual outcomes in poorly responsive neovascular age-related macular degeneration patients switched to aflibercept (last screened by PubMed on 11^th September 2015).

Study (n, eyes)	Aflibercept dosing regimen	Study design	Mean follow-up (mo)	Average age (a)	Male (%)	Mean baseline BCVA (ETDRS letters)1
Study switched group,107	Fixed dosing-3 monthly then bimonthly	Retrospective	12	81.6 (range 60-96)	44	56.3 (20/75)
Messenger et al[15],109	Clinician discretion	Retrospective	12	80.3 (range 59-96)	44	59.7 (20/64)
Grewal et al[14],21	3 loading doses, monthly or bimonthly thereafter	Prospective	12	80.7 (±4.5 SD)	43	64 (20/53)
Arcinue et al[16],63	Bimonthly (no monthly loading). Switched to monthly if persistent fluid	Retrospective	12	81 (IQR 76-87)	41	65 (20/50)
Singh et al[17],26	Fixed dosing-3 monthly, then bimonthly	Prospective	6	78 (range 69-90)	-	56.4 (20/75)
Wykoff et al[12],46	3 loading, one at month 5. IPRN at months 4 and 6	Prospective	6	77.8 (range 55-95)	48	74.2 (20/33)
Kumar et al[11],34	3 monthly, follow-up at 6 months	Retrospective	6	79 (IQR 72-84)	29	56.5 (20/74)
Gharbiya et al[10],31	3 monthly, then PRN dosing	Retrospective	6	70.1 (range 60-86)	30	42.5 (20/142)
Ferrone et al[9],221	Clinician discretion (3 injections 4-9wk apart).	Retrospective	6	83	33	66 (20/48)
Cho et al[8],28	Treat and extend	Retrospective	6	80.68 (range 62-95)	50	59 (20/66)
Chang et al[7],49	Fixed dosing-3 monthly, then bimonthly	Retrospective	6	77.8 (±7.5 SD)	43	60.5 (20/62)
Bakall et al[6],36	Treat and extend after 3 loading doses	Retrospective	6	79 (range 60-88)	42	62.5 (20/56)

¹Where previous studies have reported BCVA in logMAR, this was converted to ETDRS letter equivalents using a published method^[24]. BCVA: Best-corrected visual acuity; CRT: Central retinal thickness; ETDRS: Early Treatment Diabetic Retinopathy Study; IQR: Interquartile range; SD: Standard deviation.